Home/Filings/4/0001104659-20-080559
4//SEC Filing

Novartis Bioventures Ltd 4

Accession 0001104659-20-080559

CIK 0001722271other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 4:16 PM ET

Size

15.6 KB

Accession

0001104659-20-080559

Insider Transaction Report

Form 4
Period: 2020-06-30
Transactions
  • Conversion

    Common Stock

    2020-06-30+856,262856,262 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2020-06-30199,9960 total(indirect: See Footnote)
    Common Stock (199,996 underlying)
  • Conversion

    Common Stock

    2020-06-30+199,9961,056,258 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-30$17.00/sh+125,000$2,125,0001,181,258 total(indirect: See Footnote)
  • Conversion

    Series A Preferred Stock

    2020-06-30856,2620 total(indirect: See Footnote)
    Common Stock (856,262 underlying)
NOVARTIS AG
10% Owner
Transactions
  • Conversion

    Common Stock

    2020-06-30+856,262856,262 total(indirect: See Footnote)
  • Conversion

    Series A Preferred Stock

    2020-06-30856,2620 total(indirect: See Footnote)
    Common Stock (856,262 underlying)
  • Conversion

    Common Stock

    2020-06-30+199,9961,056,258 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2020-06-30199,9960 total(indirect: See Footnote)
    Common Stock (199,996 underlying)
  • Purchase

    Common Stock

    2020-06-30$17.00/sh+125,000$2,125,0001,181,258 total(indirect: See Footnote)
Footnotes (3)
  • [F1]On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  • [F2]Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
  • [F3]On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Documents

1 file

Issuer

Akouos, Inc.

CIK 0001722271

Entity typeother
IncorporatedBermuda

Related Parties

1
  • filerCIK 0001297709

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:16 PM ET
Size
15.6 KB